102 related articles for article (PubMed ID: 9767028)
1. Reward for persistence in substance P research.
Wahlestedt C
Science; 1998 Sep; 281(5383):1624-5. PubMed ID: 9767028
[No Abstract] [Full Text] [Related]
2. [Substance P receptor antagonists--a new antidepressive and anxiolytic mechanism?].
Lieb K; Fiebich BL; Berger M
Nervenarzt; 2000 Sep; 71(9):758-61. PubMed ID: 11042872
[TBL] [Abstract][Full Text] [Related]
3. Distinct mechanism for antidepressant activity by blockade of central substance P receptors.
Kramer MS; Cutler N; Feighner J; Shrivastava R; Carman J; Sramek JJ; Reines SA; Liu G; Snavely D; Wyatt-Knowles E; Hale JJ; Mills SG; MacCoss M; Swain CJ; Harrison T; Hill RG; Hefti F; Scolnick EM; Cascieri MA; Chicchi GG; Sadowski S; Williams AR; Hewson L; Smith D; Carlson EJ; Hargreaves RJ; Rupniak NM
Science; 1998 Sep; 281(5383):1640-5. PubMed ID: 9733503
[TBL] [Abstract][Full Text] [Related]
4. Substance-P antagonists: a new treatment for depression?
Nutt D
Lancet; 1998 Nov; 352(9141):1644-6. PubMed ID: 9853433
[No Abstract] [Full Text] [Related]
5. Can the placebo be the cure?
Enserink M
Science; 1999 Apr; 284(5412):238-40. PubMed ID: 10232967
[No Abstract] [Full Text] [Related]
6. Neurokinin-1 receptor antagonists as novel antidepressants: trials and tribulations.
Hafizi S; Chandra P; Cowen J
Br J Psychiatry; 2007 Oct; 191():282-4. PubMed ID: 17906236
[TBL] [Abstract][Full Text] [Related]
7. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.
Keller M; Montgomery S; Ball W; Morrison M; Snavely D; Liu G; Hargreaves R; Hietala J; Lines C; Beebe K; Reines S
Biol Psychiatry; 2006 Feb; 59(3):216-23. PubMed ID: 16248986
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with substance P receptor (NK1) antagonists in depression.
Ranga K; Krishnan R
J Clin Psychiatry; 2002; 63 Suppl 11():25-9. PubMed ID: 12562140
[TBL] [Abstract][Full Text] [Related]
9. Aprepitant: a novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma.
Ladizinski B; Bazakas A; Olsen EA
J Am Acad Dermatol; 2012 Nov; 67(5):e198-9. PubMed ID: 23062910
[No Abstract] [Full Text] [Related]
10. NK1 receptor antagonists for depression: Why a validated concept was abandoned.
Rupniak NMJ; Kramer MS
J Affect Disord; 2017 Dec; 223():121-125. PubMed ID: 28753469
[TBL] [Abstract][Full Text] [Related]
11. Substance P: a new era, a new role.
DeVane CL
Pharmacotherapy; 2001 Sep; 21(9):1061-9. PubMed ID: 11560196
[TBL] [Abstract][Full Text] [Related]
12. Aprepitant (EMEND): the role of substance P in nausea and vomiting.
Prommer E
J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609
[TBL] [Abstract][Full Text] [Related]
13. MK 869. L 754030, MK 0869.
Drugs R D; 1999 Oct; 2(4):249-50. PubMed ID: 10659402
[No Abstract] [Full Text] [Related]
14. Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists.
Rupniak NM
Curr Opin Investig Drugs; 2002 Feb; 3(2):257-61. PubMed ID: 12020057
[TBL] [Abstract][Full Text] [Related]
15. Substance P antagonists: meet the new drugs, same as the old drugs? Insights from transgenic animal models.
Santarelli L; Saxe MD
CNS Spectr; 2003 Aug; 8(8):589-96. PubMed ID: 12907922
[TBL] [Abstract][Full Text] [Related]
16. More on aprepitant for erlotinib-induced pruritus.
Gerber PA; Buhren BA; Homey B
N Engl J Med; 2011 Feb; 364(5):486-7. PubMed ID: 21288112
[No Abstract] [Full Text] [Related]
17. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
18. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting.
Dando TM; Perry CM
Drugs; 2004; 64(7):777-94. PubMed ID: 15025555
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.
Barrett JS; Spitsin S; Moorthy G; Barrett K; Baker K; Lackner A; Tulic F; Winters A; Evans DL; Douglas SD
J Transl Med; 2016 May; 14(1):148. PubMed ID: 27230663
[TBL] [Abstract][Full Text] [Related]
20. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography.
Hargreaves R
J Clin Psychiatry; 2002; 63 Suppl 11():18-24. PubMed ID: 12562139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
